BioAtla LLC, a San Diego, CA-based global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, received a $30m equity investment from a China-based investor group.
The proceeds will be used to accelerate the development of the company’s CAB antibody drug pipeline. This strategic investment also will advance BioAtla’s plans to collaboratively develop biotherapeutics with biopharmaceutical companies and institutions in China.
Led by Jay M. Short, Ph.D., president, chief executive officer and chairman of the board, BioAtla has developed the patent protected Conditionally Active Biologics platform for the development of a new class of immunotherapeutics that are activated in selected microenvironments within the body, such as those indicative of cancerous tumors. CABs can be generated in several different formats including naked monoclonal antibodies (mAbs), antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T cells.